This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Frontier Biotechnologies Co., Ltd
Drug Names(s): AB 001, AB-001
Description: AB-001 is a non-hydrogel based transdermal patch formulation of an NSAID for the treatment of acute pain and inflammation of the joints and muscles.
Frontier and ABsize
In November 2014, Nanjing Frontier Biotechnologies announced the acquisition of global rights to a novel topical patch for acute and chronic pain management from ABsize of Japan.
Additional information available to subscribers only: